<SEC-DOCUMENT>0001171843-25-007445.txt : 20251120
<SEC-HEADER>0001171843-25-007445.hdr.sgml : 20251120
<ACCEPTANCE-DATETIME>20251120060505
ACCESSION NUMBER:		0001171843-25-007445
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20251120
FILED AS OF DATE:		20251120
DATE AS OF CHANGE:		20251120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		251500915

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_112025.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>


</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report on Form 6-K dated November 20, 2025</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Commission File No. 1-15024)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>Novartis AG</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name of Registrant)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Lichtstrasse 35</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4056 Basel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of Principal Executive Offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&nbsp;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: right; color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"><IMG SRC="hdr.jpg" ALT=""></FONT></P>

<P STYLE="text-align: right; color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 20%"><p style="color: rgb(4,96,169); font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Novartis&nbsp;International&nbsp;AG<BR> </b><BR>
                           <font style="color: windowtext">CH-4002 Basel</font><BR>
                           <font style="color: windowtext">Switzerland</font></P>

<p style="color: #0460A9; font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">https://www.novartis.com</P>
<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">http://x.com/NovartisNews</P>



</TD></TR>
</TABLE>
<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">PRESS RELEASE</p>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: #002068; font-size: 10pt; margin: 0pt 0"><B>MEDIA &amp; INVESTOR RELEASE</B>&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<p style="text-align: right;"></p><P STYLE="text-align: left"><FONT STYLE="font-size: 12pt; color: #0460A9"><B>Novartis projects +5-6%
cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets</B></FONT><p>
 <P STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>Ad hoc announcement pursuant to Art. 53 LR</B></FONT></p>  <ul type="disc"><li style="margin-top:3pt; margin-bottom:3pt;"><FONT STYLE="font-size: 10pt"><I>Mid-term
                                            sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029
                                            guidance to +6% cc<SUP>1</SUP></I><BR /><BR /></FONT></li><li style="margin-top:3pt; margin-bottom:3pt;"><FONT STYLE="font-size: 10pt"><I>Peak
                                            sales guidance upgraded for Kisqali and Scemblix; Novartis now has eight de-risked, in-market
                                            assets with USD 3-10 billion peak sales potential</I><BR /><BR /></FONT></li><li style="margin-top:3pt; margin-bottom:3pt;"><FONT STYLE="font-size: 10pt"><I>15+
                                            potentially submission-enabling readouts expected in the next two years to fuel long-term
                                            growth </I><BR /><BR /></FONT></li><li style="margin-top:3pt; margin-bottom:3pt;"><FONT STYLE="font-size: 10pt"><I>Pipeline
                                            includes 30+ potential high-value medicines, with 10+ licensed or acquired in the past two
                                            years</I></FONT></li></ul>  <p><FONT STYLE="font-size: 10pt"><B>Basel,
                                            November 20, 2025 </B>&#8211; Novartis today rolled forward its mid-term guidance to 2025-2030
                                            with a sales CAGR of +5-6% cc. The updated outlook will be featured at its Meet Novartis
                                            Management event in London today and reflects continued strong momentum from in-market growth
                                            drivers and upcoming launches, most with issued US patent protection throughout the 2030s.</FONT></p>  <p><FONT STYLE="font-size: 10pt">Higher
                                            peak sales guidance for key brands reinforces confidence in the company&#8217;s mid-term
                                            outlook:</FONT></p>  <ul type="disc"><li style="margin-bottom:8pt;"><FONT STYLE="font-size: 10pt">Kisqali
                                            raised from USD 8 billion+ to USD 10 billion+</FONT></li><li style="margin-bottom:8pt;"><FONT STYLE="font-size: 10pt">Scemblix
                                            raised from USD 3 billion+ to USD 4 billion+</FONT></li></ul>  <p><FONT STYLE="font-size: 10pt">Novartis
                                            now has eight de-risked, in-market assets with peak sales potential of USD 3-10 billion:
                                            Kisqali, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, Fabhalta and Rhapsido.</FONT></p>  <p><FONT STYLE="font-size: 10pt">Entering
                                            a catalyst-rich period, Novartis expects 15+ potentially submission-enabling readouts over
                                            the next two years. With significant replacement power and a robust pipeline featuring 30+
                                            potential high-value medicines, including 10+ licensed or acquired in the past two years,
                                            the company is well positioned to drive long-term growth beyond 2030.</FONT></p>  <p><FONT STYLE="font-size: 10pt">Novartis
                                            delivered a core operating income margin<SUP>1</SUP> of 41.2% in the first nine months of
                                            2025 &#8211; two years ahead of plan &#8211; and expects to return to 40%+ margins by 2029,
                                            after absorbing 1-2 percentage points of dilution from the planned acquisition of Avidity
                                            Biosciences, which is expected to close in the first half of 2026, subject to completion
                                            of the separation of SpinCo from Avidity and other customary closing conditions.</FONT></p>  <p><FONT STYLE="font-size: 10pt">&#8220;As
                                            a pure-play medicines company, Novartis has delivered a strong track record of sales growth
                                            with core margin expansion,&#8221; said Vas Narasimhan, CEO of Novartis. &#8220;Looking ahead,
                                            we expect to sustain that momentum over the next five years, driven by assets we already
                                            have in hand as well as upcoming launches with multi-billion-dollar sales potential. Over
                                            the past two years, we have executed more than 30 strategic deals, bolstering our pipeline
                                            and strengthening the outlook of the business in the mid-2030s and beyond. With more than
                                            30 potential high-value medicines in our pipeline across four core therapeutic areas and
                                            advanced technology platforms, we are well positioned for long-term sustainable growth.&#8221;</FONT></p>  <p><FONT STYLE="font-size: 10pt">During
                                            the event today, investors and analysts will hear from CEO Vas Narasimhan and have the opportunity
                                            to engage with senior leaders from across the company in an open Q&amp;A format. A live webcast
                                            of the event will be available on our website at&#160;https://www.novartis.com/investors/event-calendar,
                                            along with a copy of the CEO presentation. A replay will be available once the event has
                                            concluded.</FONT></P>

<P><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P><FONT STYLE="font-size: 10pt">&nbsp;</FONT></p>  <p><FONT STYLE="font-size: 10pt"><B>Disclaimer</B><BR />This
                                            press release contains forward-looking statements within the meaning of the United States
                                            Private Securities Litigation Reform Act of 1995, that can generally be identified by words
                                            such as &#8220;anticipate,&#8221; &#8220;can,&#8221; &#8220;will,&#8221; &#8220;continue,&#8221;
                                            &#8220;ongoing,&#8221; &#8220;growth,&#8221; &#8220;launch,&#8221; &#8220;expect,&#8221;
                                            &#8220;expand,&#8221; &#8220;deliver,&#8221; &#8220;accelerate,&#8221; &#8220;guidance,&#8221;
                                            &#8220;outlook,&#8221; &#8220;priority,&#8221; &#8220;potential,&#8221; &#8220;momentum,&#8221;
                                            &#8220;commitment,&#8221; &#8220;on track,&#8221; or similar expressions, or by express or
                                            implied discussions regarding potential new products, potential new indications for existing
                                            products, potential product launches, or regarding potential future revenues from any such
                                            products; or regarding results of ongoing clinical trials; or regarding potential future,
                                            pending or announced transactions; regarding potential future sales or earnings; or by discussions
                                            of strategy, plans, expectations or intentions, including discussions regarding our continued
                                            investment into new R&amp;D capabilities and manufacturing; or regarding our capital structure.
                                            Such forward-looking statements are based on the current beliefs and expectations of management
                                            regarding future events and are subject to significant known and unknown risks and uncertainties.
                                            Should one or more of these risks or uncertainties materialize, or should underlying assumptions
                                            prove incorrect, actual results may vary materially from those set forth in the forward-looking
                                            statements. You should not place undue reliance on these statements. There can be no guarantee
                                            that the investigational or approved products described in this press release will be submitted
                                            or approved for sale or for any additional indications or labeling in any market, or at any
                                            particular time. Nor can there be any guarantee that such products will be commercially successful
                                            in the future. Neither can there be any guarantee that the expected benefits or synergies
                                            from the transactions described in this press release will be achieved in the expected timeframe,
                                            or at all. In particular, our expectations could be affected by, among other things: uncertainties
                                            concerning global healthcare cost containment, including ongoing government, payer and general
                                            public pricing and reimbursement pressures and requirements for increased pricing transparency;
                                            uncertainties regarding the success of key products, commercial priorities and strategy;
                                            uncertainties in the research and development of new products, including clinical trial results
                                            and additional analysis of existing clinical data; our ability to obtain or maintain proprietary
                                            intellectual property protection, including the ultimate extent of the impact on Novartis
                                            of the loss of patent protection and exclusivity on key products; uncertainties regarding
                                            our ability to realize the strategic benefits, operational efficiencies or opportunities
                                            expected from our external business opportunities; uncertainties in the development or adoption
                                            of potentially transformational digital technologies, including artificial intelligence,
                                            and business models; uncertainties surrounding the implementation of our new IT projects
                                            and systems; uncertainties regarding potential significant breaches of information security
                                            or disruptions of our information technology systems; uncertainties regarding actual or potential
                                            legal proceedings, including regulatory actions or delays or government regulation related
                                            to the products and pipeline products described in this press release; safety, quality, data
                                            integrity, or manufacturing issues; our performance on and ability to comply with environmental,
                                            social and governance measures and requirements; major macroeconomic and geo- and socio-political
                                            developments, including the impact of any potential tariffs on our products or the impact
                                            of war in certain parts of the world; uncertainties regarding future global exchange rates;
                                            uncertainties regarding future demand for our products; and other risks and factors referred
                                            to in Novartis AG&#8217;s most recently filed Form 20-F and in subsequent reports filed with,
                                            or furnished to, the US Securities and Exchange Commission. Novartis is providing the information
                                            in this press release as of this date and does not undertake any obligation to update any
                                            forward-looking statements as a result of new information, future events or otherwise.</FONT></p>  <p><FONT STYLE="font-size: 10pt"><B>Additional
                                            information and Where to Find It</B><BR />On October 26, 2025, Novartis announced an agreement
                                            to acquire Avidity Biosciences, Inc. Under the terms of the transactions, Novartis, through
                                            a merger with a newly formed indirect wholly owned subsidiary, will acquire all outstanding
                                            shares of Avidity. The transaction is expected to close in the first half of 2026, subject
                                            to the completion of the spin-off or a sale by Avidity of SpinCo and other customary closing
                                            conditions, including receipt of regulatory approvals and the approval of Avidity stockholders.</FONT></p>  <p><FONT STYLE="font-size: 10pt">In
                                            connection with the spin-off or sale of SpinCo and the merger (the &#8220;Transactions&#8221;),
                                            Novartis, Avidity and SpinCo intend to file relevant documents with the Securities and Exchange
                                            Commission (the &#8220;SEC&#8221;), including a preliminary and definitive proxy statement
                                            to be filed by Avidity. The definitive proxy statement and proxy card will be delivered to
                                            the stockholders of Avidity in advance of the special meeting relating to the Transactions.
                                            This document is not a substitute for the proxy statement or any other document that may
                                            be filed by Avidity with the SEC. AVIDITY&#8217;S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE
                                            PROXY STATEMENT IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY
                                            EACH OF NOVARTIS AND AVIDITY WITH THE SEC IN CONNECTION WITH THE TRANSACTIONS OR INCORPORATED
                                            BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS
                                            AND THE PARTIES TO THE TRANSACTIONS. Investors and security holders will be able to obtain
                                            a free copy of the proxy statement and such other documents containing important information
                                            about Novartis and Avidity, once such documents are filed with the SEC, through the website
                                            maintained by the SEC at www.sec.gov. Novartis and Avidity make available free of charge
                                            at the Novartis website at www.novartis.com/investors/financial-data/sec-filings and Avidity&#8217;s
                                            website at investors.aviditybiosciences.com/sec-filings, respectively, copies of documents
                                            they file with, or furnish to, the SEC.</FONT></p>  <p><FONT STYLE="font-size: 10pt"><B>Participants
                                            in the Solicitation</B><BR />This press release does not constitute a solicitation of a proxy.
                                            Novartis, Avidity and their respective directors, executive officers and certain employees
                                            may be deemed to be participants in the solicitation of proxies from the stockholders of
                                            Avidity in connection with the Transactions. Information regarding the special interests
                                            of these directors and executive officers in the Transactions will be included in the definitive
                                            proxy statement referred to above. Security holders may also obtain information regarding
                                            the names, affiliations and interests of the Novartis directors and executive officers in
                                            the Novartis Annual Report on Form 20-F for the fiscal year ended December 31, 2024, which
                                            was filed with the SEC on January 31, 2025. Security holders may obtain information regarding
                                            the names, affiliations and interests of Avidity&#8217;s directors and executive officers
                                            in Avidity&#8217;s definitive proxy statement on Schedule 14A, which was filed with the SEC
                                            on April 29, 2025. To the extent the holdings of Avidity&#8217;s securities by Avidity&#8217;s
                                            directors and executive officers have changed since the amounts set forth in Avidity&#8217;s
                                            definitive proxy statement for its 2025 annual meeting of stockholders, such changes have
                                            been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements
                                            of Change in Ownership on Form 4 filed with the SEC. These documents (when available) may
                                            be obtained free of charge from the SEC&#8217;s website at www.sec.gov, the Novartis website
                                            at https://www.novartis.com and Avidity&#8217;s website at investors.aviditybiosciences.com/sec-filings.
                                            The contents of the websites referenced above are not deemed to be incorporated by reference
                                            into the proxy statement.</FONT></P>

<P><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P><FONT STYLE="font-size: 10pt">&nbsp;</FONT></p>  <p><FONT STYLE="font-size: 10pt"><B>No
                                            Offer or Solicitation</B><BR />This press release is for informational purposes only and
                                            is not intended to and does not constitute, or form part of, an offer, invitation or the
                                            solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell
                                            or otherwise dispose of any securities, or the solicitation of any vote or approval in any
                                            jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale,
                                            issuance or transfer of securities in any jurisdiction in contravention of applicable law.</FONT></p>  <p><FONT STYLE="font-size: 10pt"><B>About
                                            Novartis </B><BR />Novartis is an innovative medicines company. Every day, we work to reimagine
                                            medicine to improve and extend people&#8217;s lives so that patients, healthcare professionals
                                            and societies are empowered in the face of serious disease. Our medicines reach nearly 300
                                            million people worldwide.</FONT></p>  <p><FONT STYLE="font-size: 10pt">Reimagine
                                            medicine with us: Visit us at <B>https://www.novartis.com</B> and connect with us on <B>LinkedIn</B>,
                                            <B>Facebook</B>, <B>X/Twitter</B> and <B>Instagram</B>.</FONT></p>  <p align="center"><FONT STYLE="font-size: 10pt">#
                                            # #</FONT></p> <table style="width:100%; border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="max-width:51%; width:100%; min-width:51%;;vertical-align: top ; "><FONT STYLE="font-size: 10pt"><B>Novartis
                                            Media Relations</B><BR />E-mail: media.relations@novartis.com<BR /><BR /> &#160;</FONT></td></tr><tr><td style="width:100%;;vertical-align: top ; "><FONT STYLE="font-size: 10pt"><B>Novartis
                                            Investor Relations</B><BR /><BR /> Central investor relations line: +41 61 324 7944<BR /><BR />
                                            E-mail: investor.relations@novartis.com<BR /><BR /> &#160;</FONT></td></tr></table> <p><FONT STYLE="font-size: 10pt"><SUP>1</SUP>
                                            Constant currencies and core results are non-IFRS measures. An explanation of non-IFRS measures
                                            can be found on page 42 of the Novartis Third Quarter and Nine Months Condensed Interim Financial
                                            Report.</FONT></p> </p><p />
<P STYLE="margin: 0pt 0; font-size: 10pt"></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 20, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL
    PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Financial Reporting and Accounting</font></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>hdr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 hdr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !6 4(# 2(  A$! Q$!_\0
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M?W:[G[NW6M&DH[5])2I0I1Y8*R/&G.4WS2=V.HHHK8DI:AIMEJMH]I?VT5Q
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;<  8 HHKFE.4W[SN7!);$E%%%2:!1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ^ ?0# 2(  A$! Q$!_\0
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M3FDL9#!05*K45667X:EC<6I2@G&FJ>%K0J1<VN>5XQ^";7V71117*=P4444
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M80KRPV-R_&3J8^I0KT['BXWC;-'GWAKF6"S'"_ZB>(,Z5&#JY)A)8_ YCB<
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MDH8G'X7$8WZK/+<%B\QQ=7%8;&8?"QP.!=.GC,7A\7B,-AZ&.H86O6HT,1+
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M_AK\9O%$GC2\T7XB^"?A;=>%=??P[/:CQ/I"ZW)9>(=0_<']@+XK?L\_%O\
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MD[]D[P_^SO\ !C6/V6?VM_\ @GM^T%\:OB'X.\2>-=&\-^._@_'K_C;X/_M
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5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
